← Leaderboards
Hildegard Schuller
University Of Tennessee Knoxville
$6,873,654
Attributed
$6,873,654
Total exposure
6
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.1M · FY2005–13$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
Funding mix
By agency
NIH$6,873,654 · 6
By mechanism
R01$5,723,654 · 4
RC1$1,000,000 · 1
S10$150,000 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Tennessee Knoxville
Same institution · by research overlap
- Hwa-Chain Robert Wang$1,155,125
Others in their field
Top investigators on “Cell Line”
- David Heimbrook · Leidos Biomedical Research, Inc.$236,973,333
- Dennis R. Burton · Scripps Research Institute$203,685,614
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$177,001,772
- John M Lachin · George Washington University$118,672,444
- David M Nathan · Massachusetts Institute Of Technology$118,672,444
- Fred M Gordin · Social And Scientific Systems, Inc.$82,802,056
Research focus
Cell LineAdenocarcinomaNitrosaminesNicotineHamstersCyclic AmpPancreatitisCellsBaseNicotinic ReceptorsMalignant NeoplasmsAdrenergicAdrenergic AgentsAminobutyric AcidsLeadMortality Vital StatisticsImmunohistochemistryIn VitroAdenylate CyclaseEpinephrineAgonistAdenocarcinoma CellGamma-Aminobutyric AcidIn Vivo
Grant awards (25)
GABA-B-R-mediated prevention of pancreatic cancer$263,148
R01 · FY2013 · CA · contact PI
GABA-B-R-mediated prevention of pancreatic cancer$280,393
R01 · FY2012 · CA · contact PI
The GABA-B receptor is a novel drug target for pancreatic cancer$264,476
R01 · FY2012 · CA · contact PI
GABA-B-R-mediated prevention of pancreatic cancer$280,800
R01 · FY2011 · CA · contact PI
The GABA-B receptor is a novel drug target for pancreatic cancer$264,476
R01 · FY2011 · CA · contact PI
Modulation of cancer prevention by social stress$500,000
RC1 · FY2010 · CA · contact PI
GABA-B-R-mediated prevention of pancreatic cancer$289,868
R01 · FY2010 · CA · contact PI
The GABA-B receptor is a novel drug target for pancreatic cancer$272,655
R01 · FY2010 · CA · contact PI
Modulation of cancer prevention by social stress$500,000
RC1 · FY2009 · CA · contact PI
GABA-B-R-mediated prevention of pancreatic cancer$290,216
R01 · FY2009 · CA · contact PI
The GABA-B receptor is a novel drug target for pancreatic cancer$272,655
R01 · FY2009 · CA · contact PI
Transplancental Pancreatic Carcinogenesis by NNK$282,794
R01 · FY2006 · CA · contact PI
Preclin. model for prevention of NSCLC in former smokers$31,622
R01 · FY2006 · CA · contact PI
NNK, Beta-Adrenergic AA Release and Lung Cancer$289,962
R01 · FY2005 · CA
Transplancental Pancreatic Carcinogenesis by NNK$289,600
R01 · FY2005 · CA
Preclin. model for prevention of NSCLC in former smokers$289,600
R01 · FY2005 · CA
NNK, Beta-Adrenergic AA Release and Lung Cancer$289,962
R01 · FY2004 · CA
Preclin. model for prevention of NSCLC in former smokers$289,600
R01 · FY2004 · CA
Transplancental Pancreatic Carcinogenesis by NNK$289,600
R01 · FY2004 · CA
NNK, Beta-Adrenergic AA Release and Lung Cancer$289,962
R01 · FY2003 · CA
Transplancental Pancreatic Carcinogenesis by NNK$289,600
R01 · FY2003 · CA
Preclin. model for prevention of NSCLC in former smokers$289,600
R01 · FY2003 · CA
NNK, Beta-Adrenergic AA Release and Lung Cancer$272,315
R01 · FY2002 · CA
FACS VANTAGE SE CELL SORTER/FLOW CYTOMETER$150,000
S10 · FY2000 · RR
TRANSPLACENTAL PANCREATIC CARCINOGENESIS BY NNK$50,750
R01 · FY2000 · CA